TB vax in spotlight as potential Type 1 diabetes cure; Trial analysis helps ease Bydureon heart rhythm worries;

  @FierceBiotech: FDA shoots down Pfizer, Pain Therapeutics drug. Story | Follow @FierceBiotech

> A cheap, generic  tuberculosis vaccine is in the spotlight at the ADA meeting as a potential new treatment for Type 1 diabetes.  Investigators say that BCG appeared to halt the process which triggers the disease. Story

> Eli Lilly and its partners on the Bydureon program say that an analysis of a recent trial could find no evidence of a link between the drug and prolonged heart rhythms. Lilly, Amylin and Alkermes were ordered by the FDA to do a new study of the drug specifically to examine its potential impact on heart rhythm. The companies said the new analysis was "encouraging." Report

> Redwood Bioscience says it has raised an undisclosed amount of money from Takeda Ventures, the venture arm of the big Japanese pharma company. Story

> Tachi Yamada, the former head of global health for the Bill & Melinda Gates Foundation, has joined on as senior executive in residence at Frazier Healthcare Ventures. Report

> The EMA has accepted Millennium's drug application for the antibody-drug conjugate Adcetris (brentuximab vedotin). Report

> The FDA has accepted Columbia Lab's new drug application for Prochieve (progesterone gel) for the reduction of risk of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy. Release

Pharma News

@FiercePharma: High court rules against Vermont in data-mining case. Report | Follow @FiercePharma

> Shire wins EMA blessing for Replagal plant. Report

> Packaging problems prompt Endo painkiller recall. Story

> Good news, bad news from diabetes gathering. Article

> Roche poised for Avastin showdown at FDA. News

> FDA urges low dosing on anemia meds. Report

> France moves to block Multaq reimbursement. Item

Biotech IT News

> Gaming, simulation combine to treat PTSD in soldiers. Story

> Cmed names ePRO vet Rotherman to board. Report

> Shire, Mediciglobal hear big bang of social media in e-recruitment. Article

> Virtify, in hosting deal, flies structured-content flag despite EU snub. News

> Safe-Biopharma teams with Verizon, furthers NCI work. Report

> Pfizer's virtual trial: Open-source meets old pharma. Article

Medical Device News

> BioMerieux unveils quicker salmonella test. Report

> Smith & Nephew buys TENET Medical Engineering. Item

> Porton calls 3M suit 'false and reckless.' Story

> St. Jude device eases migraines, but can it convince the FDA? Article

> J&J opens Chinese innovation center. News

And Finally... A class of antiretroviral drugs used to combat AIDS evidently triggers premature aging, according to a new study. Report

Suggested Articles

The takeover centers on a near-approval anti-CGRP antibody that could address Lundbeck’s need for near-term revenue drivers.

Amplyx revealed early data for its lead program in candidemia and licensed a phase 2-ready program for BK virus infection from Novartis.

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”